Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 12:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 4,637 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Be Specific Clear all
Completed Not applicable Interventional Results available

A Prospective Study Evaluating the Use of Intraoperative Stroke Volume Variation Via the FloTrac Device to Guide Fluid and Vasopressor Management in Head and Neck Free Flaps

NCT02186938
View directory record Official record
Conditions
Head and Neck Cancer, Patients Requiring a Free Flap Surgery
Interventions
FloTrac
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Oct 25, 2026, 12:27 PM EDT
Terminated Not applicable Interventional Results available

Early Psychological Intervention to Prevent Cardiovascular Event-Induced PTSD (REACH Sub-study)

NCT03605693
View directory record Official record
Conditions
Acute Coronary Syndrome, TIA, Stroke, Cardiac Arrest, PTSD
Interventions
Written Exposure Therapy
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 25, 2026, 12:27 PM EDT
Completed Phase 1 Interventional Results available

A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors

NCT02563548
View directory record Official record
Conditions
NSCLC, Gastric Cancer
Interventions
PEGPH20, Pembrolizumab
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
28
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Encinitas, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 25, 2026, 12:27 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT05556343
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic
Interventions
MYK-224
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 25, 2026, 12:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Protecting Allies in Risky Situations

NCT04691492
View directory record Official record
Conditions
Sexual Assault, College Drinking, Behavioral Changes
Interventions
Friend-Based Motivational Interview
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 24 Years · Female only
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 25, 2026, 12:27 PM EDT
Completed Phase 1 Interventional

A Study of MEHD7945A in Combination With Cisplatin and 5-Fluorouracil (5-FU) or Paclitaxel and Carboplatin in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)

NCT01911598
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
5-FU, Carboplatin, Cisplatin, MEHD7945A, Paclitaxel
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 25, 2026, 12:27 PM EDT
Completed Not applicable Interventional

High-intensity Group Vocal Exercise to Improve Laryngeal Function in Patients With Parkinson Disease

NCT03263793
View directory record Official record
Conditions
Parkinson Disease
Interventions
Choral (group) singing therapy sessions
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
Up to 100 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Oct 25, 2026, 12:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Avocado Intake on the Nutritional Status of Families

NCT02903433
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
High-intake avocados, Low-intake avocados, Diet tips, Avocado consumption advice
Other · Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
5 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Oct 25, 2026, 12:27 PM EDT
Not yet recruiting Not applicable Interventional

Automatic Prosthetic Foot Stiffness Modulation to Improve Balance in the Real World

NCT07791433
View directory record Official record
Conditions
Lower Limb Amputation Below Knee
Interventions
Fixed stiffness prosthesis, Automatic stiffness prosthesis
Device
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 79 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 25, 2026, 12:27 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy

NCT06522932
View directory record Official record
Conditions
Non Hodgkin Lymphoma
Interventions
64Cu-GRIP B, Positron Emission Tomography (PET), Optional tumor biopsy
Drug · Procedure
Lead sponsor
Michael Randall
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Oct 25, 2026, 12:27 PM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

NCT03013998
View directory record Official record
Conditions
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
Biological · Other · Drug
Lead sponsor
Beat AML, LLC
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2032
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 25, 2026, 12:27 PM EDT
Completed Not applicable Interventional Results available

Kids FACE FEARS Comparative Effectiveness Research

NCT03707158
View directory record Official record
Conditions
Child Anxiety, Anxiety Disorders, Anxiety, Anxiety Symptoms, Anxiety, Mild to Moderate, Pediatric Anxiety Disorders
Interventions
Therapist-Led CBT (telehealth, office-based, or hybrid), Guided Online CBT
Behavioral
Lead sponsor
Boston Medical Center
Other
Eligibility
7 Years to 18 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
8
States / cities
Miami, Florida • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Oct 25, 2026, 12:27 PM EDT
Completed Phase 1 Interventional

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine in Treating Patients With Advanced Metastatic Solid Tumors

NCT00307255
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
gemcitabine hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 4, 2012 · Synced Oct 25, 2026, 12:27 PM EDT
Completed Not applicable Interventional

Randomized Controlled Trial of Project Body Neutrality

NCT06172452
View directory record Official record
Conditions
Depression, Eating Disorders, Body Image
Interventions
Project Body Neutrality SSI, Supportive Therapy SSI
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
13 Years to 17 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 25, 2026, 12:27 PM EDT
Completed Not applicable Interventional

Improving the Rehabilitation Process

NCT03865758
View directory record Official record
Conditions
Dementia
Interventions
IN2L computer system
Device
Lead sponsor
Penn State University
Other
Eligibility
Not listed
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Oakmont, Pennsylvania • Washington, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 28, 2020 · Synced Oct 25, 2026, 12:27 PM EDT
Terminated No phase listed Observational

Prehab Prior to Undergoing Tricuspid Intervention

NCT04665583
View directory record Official record
Conditions
Tricuspid Valve Disease, Tricuspid Regurgitation
Interventions
Prehabilitation
Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2022 · Synced Oct 25, 2026, 12:27 PM EDT
Recruiting Phase 1 Interventional

A Study of JNJ-1761981 in Participants With Solid Tumors

NCT07525141
View directory record Official record
Conditions
Neoplasms
Interventions
JNJ-1761981, Cetrelimab
Drug
Lead sponsor
Johnson & Johnson Enterprise Innovation Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Jacksonville, Florida • Rochester, Minnesota • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 25, 2026, 12:27 PM EDT
Withdrawn Phase 1 Interventional

Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma

NCT01618253
View directory record Official record
Conditions
Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatoma, Liver Cancer
Interventions
Sorafenib, Conventional fractionation (2 Gy per day) external beam radiation therapy
Drug · Radiation
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 25, 2026, 12:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Efficiency of Task Switching and Multi-tasking

NCT03685266
View directory record Official record
Conditions
Task Performance and Analysis, Efficiency
Interventions
Observation
Other
Lead sponsor
University of Hawaii
Other
Eligibility
Not listed
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Oct 25, 2026, 12:27 PM EDT
Completed Not applicable Interventional Results available

Motivational Interviewing to Enhance Behavioral Change in Older Adults With Hoarding Disorder

NCT05237466
View directory record Official record
Conditions
Hoarding Disorder
Interventions
RECLAIM: Reducing Clutter and Increasing Meaning, Sorting Practice
Behavioral
Lead sponsor
Mississippi State University
Other
Eligibility
60 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Starkville, Mississippi
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 25, 2026, 12:27 PM EDT
Completed Phase 3 Interventional

Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx

NCT04935177
View directory record Official record
Conditions
Kidney Transplantation in Highly Sensitized Patients
Interventions
Imlifidase, PLEX, IVIg, Anti-CD20 antibodies, Eculizumab, Remain on wait list
Drug · Procedure · Other
Lead sponsor
Hansa Biopharma AB
Industry
Eligibility
18 Years to 70 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 25, 2026, 12:27 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

NCT05624554
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Nemtabrutinib, Fludarabine, Cyclophosphamide, Bendamustine, Rituximab, Truxima, Ruxience, Riabni
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
4
States / cities
Springdale, Arkansas • Clermont, Florida • Hattiesburg, Mississippi + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 25, 2026, 12:27 PM EDT
Not listed No phase listed Observational

A Pilot Study to Increase Utilization of GDMT in Patients With HFrEF

NCT05170165
View directory record Official record
Conditions
Heart Failure
Interventions
Using a clinical decision software to provide specific recommendation of a medication at a certain dosage
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Oct 25, 2026, 12:27 PM EDT
Completed Not applicable Interventional

Anti-Inflammatory Effects Of Frequency Specific Microcurrent (FSM) In Osteoarthritic Adults

NCT06390137
View directory record Official record
Conditions
Osteoarthritis
Interventions
Frequency Specific Microcurrent, Sham microcurrent treatment
Device
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Lakeland, Florida
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 25, 2026, 12:27 PM EDT